A Phase 4 interventional study of MK0966; rofecoxib and Comparator: naproxen tablet 500 mg in Rheumatoid Arthritis, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-25.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Arthritis, Rheumatoid by Merck & Co., Inc — 2 open to participants now, 3 under way, none of them phase 3. Arthritis, Rheumatoid · Merck & Co., Inc.
Among the 30 studies in Arthritis, Rheumatoid by Merck & Co., Inc, this one is the 3rd largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2004, is one of 2 in phase 4, and was the 2nd registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 30 studies in Arthritis, Rheumatoid by Merck & Co., Inc are open now, in 11 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Australia, Belgium, China and 8 more countries
Ages 18–75
Merck Sharp & Dohme LLC
Ages 18–75
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 61 across the 20 interventional studies, 440 across the 10 observational. Of the 25 that completed or were terminated, 18 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,169 studies on the registry; 134 are open to participants now.
Of its 505 completed or terminated interventional studies of FDA-regulated products, 372 (74%) have results posted.
1 of the studies in Arthritis, Rheumatoid by Merck & Co., Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07895524Merck Sharp & Dohme LLCA Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004) | 2027-10-19 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Arthritis, Rheumatoid by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to compare rofecoxib versus naproxen in the treatment of Chinese patients with rheumatoid arthritis.
Inclusion Criteria:
Tender joint count
swollen joint count
patient's global assessment of disease activity
investigator's global assessment of disease activity
Patient pain assessment
patient's global assessment of response to therapy
investigator's global assessment of response to therapy
No study locations are listed for this record.
Ran from Jan 2004 to primary completion in Jul 2004, 5 months.
Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 5 months is below that.
Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naproxen